trending Market Intelligence /marketintelligence/en/news-insights/trending/kXhhJ0DI0WoK2EfrzEb2pQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

AbbVie arthritis drug meets endpoint in phase 3 trial

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

AbbVie arthritis drug meets endpoint in phase 3 trial

AbbVie Inc. said its investigational drug upadacitinib met its primary endpoint in a phase 3 trial.

The company was evaluating the drug in patients with moderate to severe rheumatoid arthritis who did not adequately respond to prior therapy.

More than half the patients achieved a 20% improvement at week 12 of the trial, compared to 36% of patients who received placebo. Low disease activity was achieved by 48% of patients, compared to the 17% on placebo.

The drug is also being investigated to treat Crohn's disease, ulcerative colitis and atopic dermatitis.

Phase 3 trials of upadacitinib in psoriatic arthritis are also ongoing.